Highlights
- 1Seminars in perinatology · 2023
- 2Scientific reports · 2022
- 3American journal of respiratory cell and molecular biology · 2020
Publications
12 publications
Funding
3 grants
Active
2 grants- Co-IUL1TR002384-06Clinical and Translational Science Center - UL1National Center for Advancing Translational Sciences · 2022–2027
- KPKL2TR002385-06Clinical and Translational Science Center - KL2National Center for Advancing Translational Sciences · 2017–2027· 2 renewals
Completed grants (1)
- Co-IR01AI168994-01A1Innate immune regulation of lung inflammation through mitochondrial dynamicsNational Institute of Allergy and Infectious Diseases · 2023–2025
Clinical research
3 studies
Active
1 study- PIDisbalance of Sphingolipids in Bronchopulmonary DysplasiaWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2022)
Completed & closed trials (2)
- PINCT05285982An Open-label Trial of the Long-term Safety and Tolerability of Nintedanib Per os, on Top of Standard of Care, Over at Least 3 Years, in Children and Adolescents With Clinically Significant Fibrosing Interstitial Lung Disease (InPedILD®-ON)PHASE3 · Boehringer Ingelheim Pharmaceuticals, Inc. (Germany) · IRB STUDY CLOSURE (as of 2025)Lung Diseases, Interstitial
- PINCT04093024A Double Blind, Randomised, Placebo-controlled Trial to Evaluate the Dose-exposure and Safety of Nintedanib Per os on Top of Standard of Care for 24 Weeks, Followed by Open Label Treatment With Nintedanib of Variable Duration, in Children and Adolescents (6 to 17 Year-old) With Clinically Significant Fibrosing Interstitial Lung DiseasePHASE3 · Boehringer Ingelheim Pharmaceuticals, Inc. (Germany) · IRB STUDY CLOSURE (as of 2022)Lung Diseases, Interstitial